Further, while the addition of S63845 or A-1331852 to nilotinib treatment increased the amount of cell death observed over nilotinib alone in healthy cells, this effect was greater in the myeloid BP-CML cells (nilotinib+VEN: +20.15% cell death over nilotinib alone, p = 0.0054; nilotinib+S63: +23.60%, p = 0.0069; nilotinib+A13: +15.63%; p = 0.0017), indicating that co-inhibition of BCL-2 prosurvival proteins, particularly BCL-2 or MCL-1, with nilotinib could be a promising therapeutic strategy (Fig. 8A, Supplementary Table 6). Here, BCL2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.